Clinical and Morphological Side‐effects of Busulfan (Myleran) Treatment

Intersitial pneumonia and pulmonary fibrosis developed in a 72-year-old man during therapy with cyclophosphamide, vincristine, and prednisone. After extensive investigations, including an open lung biopsy, cyclophosphamide appeared to be the cause of the pulmonary disease. Complete disappearance of tachypnea and the pulmonary infiltrates occurred after the discontinuation of cyclophosphamide and the institution of prednisone therapy. We concluded that the diffuse pulmonary disease in this patient was a result of cyclophosphamide therapy. The clinical and pathologic findings in this case and a review of the literature of cyclophosphamide pulmonary toxicity are reported.

show abstract

Eye toxicity of cancer chemotherapy: A review of the literature

Griffin

Garnick

1981

Cancer

View full text Add to dashboard Cite

Eye toxicity from cancer chemotherapy is uncommon, but important because of the debility caused by loss of vision. The literature describing eye toxicity is reviewed for commonly used antineoplastic agents.Cancer 48:1539-1549, 1981. HE UTILITY OF ANTINEOPLASTIC AGENTS is fre-T quently limited by toxic side effects such as prolonged myelosuppression, peripheral neuropathy , nausea, and vomiting. Ocular toxicity, though uncommon, may be very disabling. This report discusses the clinical manifestations and pathophysiology of the ocular side effects associated with commonly used antineoplastic agents. The toxic effects of combining systemic cancer chemotherapy with radiotherapy or intrathecal therapy is also reviewed. Chemotherapeutic Agents Busulfan and DibromomannitolBusulfan (Myleran) is an alkylating agent used in the treatment of chronic myelogenous leukemia (CML). It commonly produces bone marrow suppression, and long-term use may lead to pulmonary f i b r o s i~.~~~~~~ In preclinical toxicology studies, rats given busulfan, 12.5 mglkg, developed reduced mitotic activity in the lens epithelium and nuclear disintigration with chromatin a g g r e g a t i~n .~~ When rats were fed busulfan daily at 1-2.5 mg/kg/day, anterior and posterior subcapsular cataracts developed after 4-5 weeks. In similar studies with dibromomannitol, an agent also useful in treating CML, chronic feeding of the drug to rats produced posterior subcapsular cataracts (PSC).I2OIn a clinical study, 45 patients with chronic myelog-

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Clinical and Morphological Side‐effects of Busulfan (Myleran) Treatment

Cited by 37 publications

References 17 publications

Sicca Syndrome in a Patient With Toxic Reaction to Busulfan

Sicca Syndrome in a Patient With Toxic Reaction to Busulfan

Cyclophosphamide therapy and interstitial pulmonary fibrosis

Eye toxicity of cancer chemotherapy: A review of the literature

Contact Info

Product

Resources

About